HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER
非那雄胺和硒干预前列腺癌中的缺氧和 PRX1
基本信息
- 批准号:7254394
- 负责人:
- 金额:$ 29.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAndrogen ReceptorApoptosisApoptoticBasement membraneBiologicalBlood VesselsBlood flowCancer ControlCell Culture SystemCell SurvivalCellsClonal ExpansionDevelopmentDiffusionElevationFamilyFinasterideHumanHypoxiaIn VitroInterventionMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of prostateMolecularOxidation-ReductionOxygenPartial PressurePhenotypePopulationPreventiveProliferatingProstateProtein FamilyProteinsReceptor SignalingRegulationResistanceSeleniumShunt DeviceSignal TransductionStressTestingTimeTranscriptional ActivationTumor OxygenationUp-RegulationXenograft Modelbasecancer cellhuman tissueknock-downmembernovelpressurereceptor functionresponsesizesoundtissue oxygenationtranscription factortumor
项目摘要
Hypoxia is a key regulatory microenvironmental factor capable of influencing tumor development and
progression. Hypoxia is usually considered a global phenomenon, defined as an overall reduced oxygen
availability or partial pressure below critical levels. Tumor vasculature, however, is architecturally and
functionally abnormal. The tissue oxygenation/blood flow within a tumor is dynamically changing and
heterogeneous at the microenvironmental level. Hypoxia has been proposed to functions as a
microenvironmental pressure to select for a fraction of hypoxia-resistant cancer cells with an increased ability
to survive and progress. Peroxiredoxins(Prxs) are a newly described family of redox-controlling proteins. Two
highly homologous members of this protein family, Prx1 and Prx2, have been shown to affect cell survival and
increase stress resistance. However, little is known about the effects of Prx elevation in human cancers, their
influence on malignant progression and treatment response, or the regulatory mechanisms. Our preliminary
studies provide compelling evidences to support the functional relevance of hypoxiaand Prx1 (but not Prx2) in
enhancing the AR function, and suppressing apoptotic signaling. In this study, we will systematically
investigate "why"and "how" Prx1 is elevate in prostate cancer cells at the microenvironmentallevel, and study
the effect of tissue oxygenation status and Prx1level in modifying the cancer control efficacy of finasteride and
selenium. We hypothesize that dynamic changes of tissue oxygenation up-regulate Prx1 expression via
redox-sensitive transcription factors, and the dysregulated activation of these transcription factors leads to
Prx1 elevation in a subset of prostate cells within a tumor. We also hypothesize that elevated Prx1 confers an
aggressive survival phenotype to cells by enhancing AR activity, and reducing oxidative damage and
apoptosis. We correspondingly hypothesize that inhibition of Prx1 will increase the AR signaling suppressive
and cancer control efficacy of finasteride and selenium. In order to test these hypotheses, four specific aims
are proposed. In Aim 1, we will define the molecular basis of Prx1 up-regulation in prostate cancer cells. In
Aim 2, we will elucidate the mechanisms whereby Prx1 enhances AR function. In Aim 3 and Aim 4, we will
systematically investigate whether and how Prx1 modifies the cancer control efficacy of finasteride and
selenium in the context of a hypoxic tumor microenvironment. These studies will provide a sound scientific
basis upon which the regulation and function of Prx1 can be elucidated in prostate cancer, enabling the
development of novel preventive approaches to inhibit its malignant progression.
缺氧是一个关键的调控微环境因素,能够影响肿瘤的发生和发展
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOUNG-MEE PARK其他文献
YOUNG-MEE PARK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOUNG-MEE PARK', 18)}}的其他基金
Prx1 in malignant progression of prostate cancer
Prx1在前列腺癌恶性进展中的作用
- 批准号:
7218563 - 财政年份:2006
- 资助金额:
$ 29.19万 - 项目类别:
Prx1 in malignant progression of prostate cancer
Prx1在前列腺癌恶性进展中的作用
- 批准号:
7101594 - 财政年份:2006
- 资助金额:
$ 29.19万 - 项目类别:
Peroxiredoxin 1 in radiotherapy of lung cancer
过氧化还原蛋白1在肺癌放疗中的应用
- 批准号:
6814987 - 财政年份:2004
- 资助金额:
$ 29.19万 - 项目类别:
Peroxiredoxin 1 in radiotherapy of lung cancer
过氧化还原蛋白1在肺癌放射治疗中的应用
- 批准号:
7236122 - 财政年份:2004
- 资助金额:
$ 29.19万 - 项目类别:
Peroxiredoxin 1 in radiotherapy of lung cancer
过氧化还原蛋白1在肺癌放射治疗中的应用
- 批准号:
7095240 - 财政年份:2004
- 资助金额:
$ 29.19万 - 项目类别:
Peroxiredoxin 1 in radiotherapy of lung cancer
过氧化还原蛋白1在肺癌放疗中的应用
- 批准号:
6928549 - 财政年份:2004
- 资助金额:
$ 29.19万 - 项目类别:
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER
非那雄胺和硒干预前列腺癌中的缺氧和 PRX1
- 批准号:
8324492 - 财政年份:
- 资助金额:
$ 29.19万 - 项目类别:
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER
非那雄胺和硒干预前列腺癌中的缺氧和 PRX1
- 批准号:
8135361 - 财政年份:
- 资助金额:
$ 29.19万 - 项目类别:
HYPOXIA AND PRX1 IN FINASTERIDE AND SELENIUM INTERVENTION OF PROSTATE CANCER
非那雄胺和硒干预前列腺癌中的缺氧和 PRX1
- 批准号:
7930595 - 财政年份:
- 资助金额:
$ 29.19万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 29.19万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 29.19万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 29.19万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 29.19万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 29.19万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 29.19万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 29.19万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 29.19万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 29.19万 - 项目类别: